The current financial score of Protagonist Therapeutics Inc is 9.31. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 213.47M, representing a year-over-year increase of 3749.17%, while its net profit experienced a year-over-year increase of 568.35%.
The current valuation score of Protagonist Therapeutics Inc is 7.21. Its current P/E ratio is -80.42, which is -252.68% below the recent high of 122.78 and -9.34% above the recent low of -87.93.
The current earnings forecast score of Protagonist Therapeutics Inc is 8.71. The average price target is 175.62, with a high of 225.00 and a low of 150.00.
The current price momentum score of Protagonist Therapeutics Inc is 3.10. Currently, the stock price is trading between the resistance level at 155.22 and the support level at 137.68, making it suitable for range-bound swing trading.
The current institutional shareholding score of Protagonist Therapeutics Inc is 10.00. The latest institutional shareholding proportion is 118.60%, representing a quarter-over-quarter decrease of 0.99%. The largest institutional shareholder is Ken Fisher, holding a total of 170.52K shares, representing 0.01% of shares outstanding, with 220.66% increase in holdings.
The current risk assessment score of Protagonist Therapeutics Inc is 6.83. The company's beta value is 1.86. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.